NRx Pharmaceuticals Announces Further Alignment with FDA on Initiation of Registrational Trials for NRX-101 in the Treatment of Chronic PainPRNewsWire • 10/26/23
NRx Pharmaceuticals Announces Strategic Change in Development of NRX-100 (IV Ketamine) at Dawson James Small Cap Investor ConferencePRNewsWire • 10/12/23
NRx Pharma (NRXP) to Initiate Clinical Study on NRX-101, Stock UpZacks Investment Research • 10/03/23
NRx Pharmaceuticals Announces FDA Permission to Proceed on Investigational New Drug (IND) Application for NRX-101 to Treat Chronic PainPRNewsWire • 10/02/23
NRX Pharmaceuticals Announces Data Sharing Agreement Demonstrating Efficacy and Safety of Intravenous Ketamine for the Treatment of Suicidal Bipolar DepressionPRNewsWire • 09/15/23
NRx Pharmaceuticals Announces Agreement with LifeSci Associates to Provide Financial Services and SupportPRNewsWire • 09/14/23
NRx Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment ConferencePRNewsWire • 09/07/23
NRx Pharmaceuticals Announces Potent Antibacterial Activity of NRX-101 Against Common, Antibiotic Resistant Urinary PathogensPRNewsWire • 09/06/23
NRx Pharmaceuticals Announces Submission of an Investigational New Drug (IND) Application for NRX-101 in the Treatment of Chronic PainPRNewsWire • 08/30/23
NRx Pharmaceuticals Announces Definitive Purchase Agreement for Preferred Shares at $0.40 per sharePRNewsWire • 08/29/23
SHAREHOLDER ALERT: Kaskela Law LLC Announces Stockholder Investigation of NRx Pharmaceuticals, Inc. and Encourages Long-Term NRXP / BRPA Investors to Contact the FirmBusiness Wire • 08/16/23
NRx Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business UpdatePRNewsWire • 08/14/23
NRx Pharmaceuticals Announces the Licensure of a US Patent to Support Use of NRX-101™ for Chronic PainPRNewsWire • 08/07/23
NRx Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 14, 2023PRNewsWire • 08/07/23
NRXP ALERT: Levi & Korsinsky, LLP Announces an Investigation into the Fairness of NRx Pharmaceuticals Inc.'s De-SPAC MergerPRNewsWire • 06/27/23
NRx Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual ConferencePRNewsWire • 06/20/23
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of NRx Pharmaceuticals, Inc. and Encourages Long-Term NRXP / BRPA Shareholders to Contact the FirmPRNewsWire • 06/15/23
NRx Pharmaceuticals Announces Closing of $6.28 Million Registered Direct OfferingPRNewsWire • 06/09/23
NRx Pharmaceuticals, Lotus Pharmaceuticals and Alvogen Inc. Announce Collaboration to Develop and Commercialize NRX-101GlobeNewsWire • 06/05/23
NRx Pharmaceuticals to Host Corporate and Strategic Update Conference Call on Monday, June 5, 2023PRNewsWire • 06/02/23